INM Form DEF 14A: Definitive proxy statement

INMED PHARMACEUTICALS INC. Form DEF 14A: Definitive proxy statement

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

2025-11-03: Form DEF 14A; Period of report 2025-12-17; Description DEFINITIVE PROXY STATEMENT; Document ea0262858-def14a_inmed.htm.
2025-05-16: Form DEF 14A; Period of report 2025-06-13; Description PROXY STATEMENT; Document ea0239463-02.htm.
2024-10-28: Form DEF 14A; Period of report 2024-12-18; Description PROXY STATEMENT; Document ea0218812-01.htm.
2023-10-27: Form DEF 14A; Period of report 2023-12-19; Description PROXY STATEMENT; Document def14a1023_inmedpharma.htm.

Filed	Form	Period of report	Description	Document
2025-11-03	DEF 14A	2025-12-17	DEFINITIVE PROXY STATEMENT	ea0262858-def14a_inmed.htm
2025-05-16	DEF 14A	2025-06-13	PROXY STATEMENT	ea0239463-02.htm
2024-10-28	DEF 14A	2024-12-18	PROXY STATEMENT	ea0218812-01.htm
2023-10-27	DEF 14A	2023-12-19	PROXY STATEMENT	def14a1023_inmedpharma.htm
2022-10-28	DEF 14A	2022-12-15	DEFINITIVE PROXY STATEMENT	def14a0422_inmedpharm.htm
2021-10-28	DEF 14A	2021-12-17	PROXY STATEMENT	def14a1021_inmed.htm

Stock Name	Country	Market Cap	PE Ratio
Apimeds Pharmaceuticals US, Inc. (APUS)	United States	$0.008B
Ensysce Biosciences, Inc. (ENSC)	United States	$0.008B	-0.37
CNS Pharmaceuticals, Inc. (CNSP)	United States	$0.007B
EXICURE, INC. (XCUR)	United States	$0.008B	-1.54
Acurx Pharmaceuticals, Inc. (ACXP)	United States	$0.007B	-0.97
SOLIGENIX, INC. (SNGX)	United States	$0.008B
Imunon, Inc. (IMNN)	United States	$0.008B	-0.56
SYNLOGIC, INC. (SYBX)	United States	$0.007B
Bolt Biotherapeutics, Inc. (BOLT)	United States	$0.007B	-0.26
Enveric Biosciences, Inc. (ENVB)	United States	$0.007B	-0.63